Bionime Corporation

Taiwan Stock Exchange 4737.TW

Bionime Corporation Return on Equity (ROE) for the year ending December 31, 2023: 0.31%

Bionime Corporation Return on Equity (ROE) is 0.31% for the year ending December 31, 2023, a -92.88% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Bionime Corporation Return on Equity (ROE) for the year ending December 31, 2022 was 4.39%, a 3.98% change year over year.
Bionime Corporation Return on Equity (ROE) for the year ending December 31, 2021 was 4.22%, a 39.76% change year over year.
Bionime Corporation Return on Equity (ROE) for the year ending December 31, 2020 was 3.02%, a -41.90% change year over year.
Bionime Corporation Return on Equity (ROE) for the year ending December 31, 2019 was 5.20%, a -19.09% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Taiwan Stock Exchange: 4737.TW

Bionime Corporation

CEO	Mr. Chun-Mu Huang
IPO Date	Dec. 23, 2010
Location	Taiwan
Headquarters	No. 100, Daqing Street
Employees	1,111
Sector	Healthcare
Industries Medical Instruments 3D Printing Biotechnology Drugstores & Retail Pharmacies Hardware & Electronics Musical Instruments Personal Care Pharmaceuticals

Description

Bionime Corporation designs, manufactures, and sells medical instruments in China, Switzerland, the United States, Algeria, Egypt, and internationally. The company offers blood glucose monitors, as well as accessories, such as test strips and lancing devices medical equipment companies, pharmacies, and hospitals. It is also involved in the provision of biotechnology services; examining of pharmaceuticals; and selling of precision instruments. The company was incorporated in 2003 and is based in Taichung, Taiwan.

Key trends

Past 5 years